Mifepristone, a common abortion inducing medication, will remain on the market without additional restrictions after the U.S. Supreme Court unanimously rejected an anti-abortion group’s challenge to the drug’s approval.
In the high court’s first abortion-related ruling since it overturned Roe v. Wade in 2022, the nine justices ruled to change nothing about the drug’s legal status. The ruling is a rebuke to the 5th U.S. Circuit Court of Appeals and District Judge Matthew Kacsmaryk of Amarillo. The opinion was written by Justice Brett Kavanaugh, with a concurring opinion by Justice Clarence Thomas.
